M3, Inc.
10.36
USD
+0.19
(+1.89%)
ISIN
JP3435750009
Return %
Stock
S&P 500
1Y
-24.75
14.20
3Y
-56.09
81.12
5Y
-84.37
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Itaru Tanimura
- Full Time Employees
- 17,010
- Sector
- Technology services
- Industry
- Internet software/Services
- Address
- Akasaka Intercity Tokyo TY Japan 107-0052
- IPO Date
- Sep 16, 2004
- Website
- corporate.m3.com
- Similar Companies
- Business
- M3, Inc. engages in the provision of medical-related services primarily through internet-based platforms targeting physicians and healthcare professionals. The company operates through six main business segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, Overseas, and Other Emerging Businesses. Its Medical Platform segment includes m3.com, a members-only site offering medical information and tools; MR-kun, delivering daily medical updates; QOL-kun, a marketing support service for doctors; AskDoctors, a consumer service for health questions; and region-specific medical professional sites such as MDLinx in the U.S. and Doctors.net.uk in the U.K. The Evidence Solution segment supports clinical trials management and research operations. The Career Solution segment offers recruitment, job advertisement, and human resources services for medical professionals in Japan. The Site Solution segment provides management support and consulting services to medical institutions, including home-visit nursing and electronic medical records solutions. The Overseas segment extends marketing support, research, clinical trial support, and human resource services across the U.S., U.K., China, South Korea, India, France, Germany, and Spain. Founded in 2000 and headquartered in Tokyo, Japan, M3, Inc. serves pharmaceutical companies, medical device manufacturers, healthcare professionals, and medical institutions globally. Recent major company developments include multiple strategic acquisitions and business expansions: M3 acquired Kantar’s specialist healthcare research businesses to expand its global healthcare panel and research capability; it acquired Michael Allen Company in the U.S. to strengthen pharmaceutical relationships; it purchased the medical accounting and electronic health record (EHR) business from Canon Medical Systems to accelerate digital transformation in clinics through its M3 DigiKar cloud EHR system; it launched the Clinic Succession Platform to support continuity of medical institutions; it initiated an AI medical image diagnostics platform in collaboration with NOBORI; and it expanded into COVID-19 remote image diagnosis support with Alibaba and St. Marianna University School of Medicine Hospital. Additionally, M3 consolidated subsidiaries such as DailyRounds, entering medical education services in India, and CUC, Inc., which was newly listed on the Tokyo Stock Exchange Growth Market. The company also continues to advance consumer healthcare platforms, evidenced by ongoing development of LINE Healthcare remote consultation services. M3’s share repurchase program was announced recently, reflecting financial strength and shareholder returns initiatives. M3, Inc. maintains a significant presence across Japan, the U.S., Europe, India, and several Asian markets, operating platforms and services that connect healthcare professionals with pharmaceutical companies and provide comprehensive medical-related information, clinical trial support, career services, institutional management, and healthcare research solutions.
Company News
Invesco EQV International Equity Fund Q1 2026 Portfolio Review
M3 (OTCMKTS:MTHRF) Trading Up 1.7% – Time to Buy?
7 Growth Stocks to Buy Before They Mint Millionaires
M3, Inc.: Stand-Out Success Story Of Japanese Internet
3 Telehealth Stocks to Buy Even After Covid-19